Article Text

Download PDFPDF

462 Pre-selection of patients who would respond to combination of chemotherapy and low dose immunotherapy using human histoculture platform
  1. Kowshik Jaganathan1,
  2. Biswajit Das1,
  3. BV Prakash2,
  4. MS Ganesh3,
  5. Amritha Prabha3,
  6. Vijay Pillai4,
  7. Ravi Krishnappa5,
  8. V Syamkumar1,
  9. Chandan Bhowal1,
  10. M Mouniss1,
  11. M Dharanidharan1,
  12. M Rajashekar1,
  13. M Oliyarasi1,
  14. Ritu Malhotra1,
  15. K Govindraj1,
  16. Manjunath I Nandennavar4,
  17. Shashidhar V Karpurmath3,
  18. Mohit Malhotra6,
  19. Nandini P Basak1 and
  20. Satish Sankaran1
  1. 1Farcast Biosciences, Bangalore, Karnataka, India
  2. 2Sri Lakshmi Multi Speciality Hospital, Bangalore, India
  3. 3Vydehi Multi Speciality Hospital, Bangalore, Karnataka, India
  4. 4Mazumdar Shaw Medical Center Narayana Health, Bangalore, India
  5. 5JSS hospital, Mysore, Karnataka, India
  6. 6Farcast Biosciences, LLC, Pensacola, FL, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Only 1–3 % of patients with Head and Neck Squamous Cell Carcinoma (HNSCC) in low- and middle-income countries can afford Nivolumab treatment even though it is approved for recurrent and metastatic disease.1 Low Dose Nivolumab (LDN) has shown similar efficacy compared to Standard Dose Nivolumab (SDN) in renal and lung cancer.2 3 A recent study demonstrated that HNSCC patient sub-cohort treated with chemotherapy (CT) and LDN showed improved progression-free and overall survival compared to sub-cohort treated with CT alone.1 To better understand the added benefit of the combination treatment, it is important to rule out the contribution of CT alone in the responding patients that might not result in a durable response. To address this, we employed the FarcastTM TruTumor, a near native human histoculture platform which can compare multiple treatment response simultaneously for the same patient sample.

Methods Fresh surgically resected HNSCC samples (n=20) along with matched blood were collected from consented patients. Thin explants were generated and distributed into arms. These arms were treated in culture with either LDN (7.3 µg/ml) or SDN (132 µg/ml) and CT (Methotrexate (220.8µg/ml)+erlotinib (2.5µg/ml)+celecoxib (0.7µg/ml) or Paclitaxel (2.7µg/ml)+Carboplatin (37.1µg/ml) alone or CT+LDN for 72 hours. The response was evaluated using histopathology, interferon-γ (IFN-g) cytokine release and flow cytometry.

Results Both SDN and LDN treatment led to effective masking of Programmed cell death protein 1 (PD1) expression. No significant difference was observed in tumor cytotoxicity response between LDN and SDN in the same samples (n=8). Analysis of immune cell types and activation markers such as CD8+Granzyme-B+, CD8+Ki67+ T cells also showed no significant difference between LDN and SDN treatments. Comparable IFN-g response was observed in 7/8 samples.

We next compared response to CT alone or CT+LDN in the same sample (n=12). Ten out of 12 samples did not show a significant difference in tumor content on treatment with CT+LDN compared to CT alone. Five out of these 10 samples showed a significant increase in cleaved caspase expression in tumor, primarily driven by CT treatment. In two samples CT+LDN showed significant drop in tumor content but not in CT or SDN alone, clearly implicating the benefit of combination treatment.

Conclusions The FarcastTM TruTumor platform thus provides the unique opportunity to identify patients who would truly benefit from treatment with LDN+CT combination. An observational trial is underway to correlate the response observed in our platform with response of the patient in the clinic.


  1. Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Low-dose immunotherapy in head and neck cancer: A randomized study. J Clin Oncol. 2023;41(2):222–232

  2. Zhao JJ, Kumarakulasinghe NB, Muthu V, Lee M, Walsh R, Low JL, Choo J, Tan HL, Chong WQ, Ang Y, et al. Low-dose Nivolumab in renal cell carcinoma: A real-world experience. 2021;99(3):192–202

  3. Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, Kim DW, Lee JS, Heo DS. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018;3(5):e000332

Ethics Approval The Institutional Ethics Committee (IEC) from the sample collection centers approved the protocol (protocol # FCB-PROTOCOL-01) and informed consent for participation in the approved study was obtained from every donor.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.